An AI tool using echocardiograms accurately screens for cardiac amyloidosis, outperforming traditional detection methods.
Key Details
- 1AI model analyzes echocardiogram (ultrasound) images to screen for cardiac amyloidosis.
- 2Developed by Mayo Clinic and Ultromics; validated in a global, multi-ethnic cohort across 18 hospitals.
- 3Achieved 85% sensitivity and 93% specificity in detecting or ruling out cardiac amyloidosis.
- 4Outperformed existing clinical scoring systems for early diagnosis.
- 5FDA-cleared and already being implemented in multiple US hospitals.
Why It Matters
Early, accurate identification of cardiac amyloidosis is critical due to effective therapies available only at earlier disease stages. AI-based screening of routine cardiac ultrasound could substantially improve detection rates and patient outcomes, supporting broader integration of imaging AI in clinical care.
Source
EurekAlert
Related News
•EurekAlert
AI Model Predicts Growth Spurts from Pediatric Neck X-rays for Orthodontics
Korean researchers developed an AI system (ARNet-v2) that predicts children's growth spurts from neck X-rays to enhance orthodontic treatment planning.
•EurekAlert
Lunit Acquires Prognosia to Boost AI Mammography Risk Prediction
Lunit has acquired Prognosia, an AI-driven breast cancer risk prediction startup founded by WashU researchers, to accelerate clinical adoption of advanced mammography analytics.
•EurekAlert
Imaging Reveals Skull Changes and Immune Impact in Glioblastoma
Advanced imaging uncovers that glioblastoma affects the skull and immune system, not just the brain.